Artwork

Content provided by Brilliant Board Review & CME, Brilliant Board Review, and CME. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Brilliant Board Review & CME, Brilliant Board Review, and CME or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

πŸŽ™οΈ Episode 34: MS Meds After 55? Time for a Pause ?

1:16
 
Share
 

Manage episode 478124857 series 3659512
Content provided by Brilliant Board Review & CME, Brilliant Board Review, and CME. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Brilliant Board Review & CME, Brilliant Board Review, and CME or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.

Send us a text

πŸ§ͺ Study:

Patients β‰₯55 with no relapses in 5 yrs and no new lesions in 3 yrs may stop disease-modifying therapy (DMT).

No significant difference in disability progression.

🧩 Clinical Takeaway:

De-escalation strategy in stable MS may reduce cost and side effects.

Still requires close neurology follow-up.

Please visit www.Brilliantcourses.com to reflect on this activity with Learner+ platform to earn CME/CE.

  continue reading

45 episodes

Artwork
iconShare
 
Manage episode 478124857 series 3659512
Content provided by Brilliant Board Review & CME, Brilliant Board Review, and CME. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Brilliant Board Review & CME, Brilliant Board Review, and CME or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.

Send us a text

πŸ§ͺ Study:

Patients β‰₯55 with no relapses in 5 yrs and no new lesions in 3 yrs may stop disease-modifying therapy (DMT).

No significant difference in disability progression.

🧩 Clinical Takeaway:

De-escalation strategy in stable MS may reduce cost and side effects.

Still requires close neurology follow-up.

Please visit www.Brilliantcourses.com to reflect on this activity with Learner+ platform to earn CME/CE.

  continue reading

45 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide

Listen to this show while you explore
Play